Loading clinical trials...
Loading clinical trials...
A Single-arm, Dose-escalation Phase I Clinical Study on Evaluating the Tolerability, Pharmacokinetic Characteristics, Safety and Preliminary Efficacy of MT027 in Patients with Recurrent or Progressive High-grade Glioma
Conditions
Interventions
MT027 cells suspension
Locations
1
China
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
Wuhan, Hubei, China
Start Date
January 1, 2025
Primary Completion Date
June 30, 2026
Completion Date
December 30, 2026
Last Updated
December 17, 2024
NCT06829173
NCT06624371
NCT06660056
NCT06763965
NCT07472790
NCT04482933
Lead Sponsor
Suzhou Maximum Bio-tech Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions